米氮平和盐酸舍曲林治疗女性更年期抑郁障碍的随机对照研究  

A comparative study between mirtapine and sertraline intreatmnet of menopause depression

作　　者：王金龙[1] 赵和丹 

机构地区：[1]浙江嘉兴市康慈医院精神科,嘉兴314500

出　　处：《海峡药学》2011年第6期87-89,共3页Strait Pharmaceutical Journal

摘　　要：目的探讨米氮平和盐酸舍曲林治疗更年期抑郁障碍的疗效。方法将64例符合更年期首发抑郁障碍的患者随机分成米氮平组和盐酸舍曲林组。米氮平剂量1日15~45mg,舍曲林1日50~200mg,疗效采用汉密尔顿抑郁量表（HAMD）,不良反应和安全性用TESS和实验室检查评定。观察时间为期6周。结果米氮平组显效率84.38%,痊愈率53.13%,舍曲林组显效率81.25%,痊愈率46.87%,两组疗效比较差异无统计学意义（P〉0.05）。治疗后1、2周米氮平组与舍曲林组HAMD评分比较,差异有统计学意义（P〈0.01）。两组不良反应均表现较轻。结论两组疗效相当,但米氮平治疗更年期首发抑郁障碍起效时间较快,安全、值得临床推广使用。OBJECTIVE To explore the efficacy between mirtapine and sertraline treatment of menopause depression.METHODS A total of 64 patients with menopause depression were randomly divided into study group with mirtapine and control group with sertraline for the treatment of 6 weeks.They were assessed using Hamilton Rating Scale of depression（HAMD）,and Treatment Emergent Side Effect Scale（TESS）.RESULTS The response rate and remissionrate were 84.38% and 53.13% for mirtapine group and were 81.25%and 46.87% for sertraline group respectively,without ststistically significant difference between two groups.In the 1nd and 2nd weekend,the scores of HAMD in mirtapine group were significantly lower than those beforetreatment（P0.01）.But not in TESS for all times（P0.05）.CONCLUSION The efficacy of both groups are similar,but mirtapine is safe,effective and take into effect take into effect fast.

关 键 词：米氮平 舍曲林 更年期抑郁障碍 

分 类 号：R969.4[医药卫生—药理学]